Last reviewed · How we verify
Ipilimumab and nivolumab
Ipilimumab and nivolumab together block immune checkpoints (CTLA-4 and PD-1) to unleash T-cell-mediated anti-tumor immunity.
Ipilimumab and nivolumab together block immune checkpoints (CTLA-4 and PD-1) to unleash T-cell-mediated anti-tumor immunity. Used for Metastatic melanoma, Advanced renal cell carcinoma, Metastatic non-small cell lung cancer.
At a glance
| Generic name | Ipilimumab and nivolumab |
|---|---|
| Also known as | Yervoy and Opdivo, Yervoy, Opdivo, Ipilimumab (YERVOY), Nivolumab (OPDIVO) |
| Sponsor | Leiden University Medical Center |
| Drug class | Immune checkpoint inhibitor combination (CTLA-4 inhibitor + PD-1 inhibitor) |
| Target | CTLA-4 and PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ipilimumab is a CTLA-4 inhibitor that removes inhibitory signals on T cells, while nivolumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction. Combined, they work synergistically to enhance T-cell activation, proliferation, and tumor infiltration, overcoming multiple layers of immune suppression in the tumor microenvironment.
Approved indications
- Metastatic melanoma
- Advanced renal cell carcinoma
- Metastatic non-small cell lung cancer
Common side effects
- Immune-related colitis
- Immune-related pneumonitis
- Immune-related hepatitis
- Fatigue
- Rash
- Diarrhea
Key clinical trials
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (PHASE1)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (PHASE1, PHASE2)
- A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ipilimumab and nivolumab CI brief — competitive landscape report
- Ipilimumab and nivolumab updates RSS · CI watch RSS
- Leiden University Medical Center portfolio CI